Media coverage
1
Media coverage
Title Research Conversations: Risk of Cardiovascular Side Effects with Newer Hormone Therapies Degree of recognition International Media name/outlet Prostate Cancer Foundation Media type Web Country/Territory United States Date 2/07/24 Description Survival with advanced prostate cancer has improved in recent years, thanks in part to newer medicines called androgen receptor signaling inhibitors (ARSIs). ARSIs include abiraterone, apalutamide, darolutamide, and enzalutamide. However, because patients are now living longer with low testosterone levels, they are at greater risk of side effects.
PCF Young Investigator Dr. Ashwin Sachdeva and Prof. Noel Clarke of the University of Manchester in the UK discussed their recently published work showing that the risk of cardiovascular events (e.g. heart attack, stroke, blood clots) nearly doubled among patients taking ARSIs in addition to standard hormone therapy.
Watch the video to learn more about:
- How you and your doctor can consider your personal risk factors when starting treatment
- Why it’s important to work with a team – urologist, medical oncologist, primary care physician – to monitor your health
- Ways to lower your risk of cardiovascular eventsURL https://www.pcf.org/c/research-conversations-risk-of-cardiovascular-side-effects-with-newer-hormone-therapies/ Persons Ashwin Sachdeva, Noel Clarke
Research Highlights, Institutes and Platforms
- Cancer
- Manchester Cancer Research Centre